Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
Liraglutide is 31 amino acids long, whereas Tesamorelin is longer as it has a length of 44 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. Tesamorelin is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Asparagine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Glycine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Methionine, Serine, Arginine, Glutamine, Glutamine, Glycine, Glutamic acid, Serine, Asparagine, Glutamine, Glutamic acid, Arginine, Glycine, Alanine, Arginine, Alanine, Arginine, Leucine.
Liraglutide
GCG
Tesamorelin
GHRH